Hester Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
May 17, 2023 at 03:43 am EDT
Share
Hester Biosciences Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 672.99 million compared to INR 564.69 million a year ago. Revenue was INR 704.87 million compared to INR 636.61 million a year ago. Net income was INR 45.31 million compared to INR 77.23 million a year ago. Basic earnings per share from continuing operations was INR 6.72 compared to INR 10.59 a year ago.
For the full year, sales was INR 2,660.91 million compared to INR 2,350.06 million a year ago. Revenue was INR 2,812.42 million compared to INR 2,487.47 million a year ago. Net income was INR 266.27 million compared to INR 393.2 million a year ago. Basic earnings per share from continuing operations was INR 32.96 compared to INR 46.41 a year ago.
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.